Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.31 Million USD | -8.11% |
| 2022 | 3.6 Million USD | 110.14% |
| 2021 | 1.71 Million USD | 184.32% |
| 2020 | 603.47 Thousand USD | 94.04% |
| 2019 | 311 Thousand USD | 50.29% |
| 2018 | 206.93 Thousand USD | 680.14% |
| 2017 | 26.52 Thousand USD | -74.71% |
| 2016 | 104.87 Thousand USD | -59.66% |
| 2015 | 259.96 Thousand USD | 29.2% |
| 2014 | 201.21 Thousand USD | -4.57% |
| 2013 | 210.84 Thousand USD | 4.61% |
| 2012 | 201.55 Thousand USD | -94.17% |
| 2011 | 3.45 Million USD | 345861500.0% |
| 2010 | 1.00 USD | -100.0% |
| 2009 | 313.15 Thousand USD | 2333.0% |
| 2008 | 12.87 Thousand USD | -76.08% |
| 2007 | 53.79 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.06 Million USD | 22.82% |
| 2024 Q2 | 3.79 Million USD | -6.71% |
| 2023 FY | 3.31 Million USD | -8.11% |
| 2023 Q4 | 3.31 Million USD | -4.64% |
| 2023 Q1 | 3.54 Million USD | -1.55% |
| 2023 Q2 | 3.48 Million USD | -1.76% |
| 2023 Q3 | 3.47 Million USD | -0.37% |
| 2022 Q2 | 4.54 Million USD | -5.01% |
| 2022 Q3 | 4.19 Million USD | -7.69% |
| 2022 Q4 | 3.6 Million USD | -14.0% |
| 2022 Q1 | 4.78 Million USD | 178.66% |
| 2022 FY | 3.6 Million USD | 110.14% |
| 2021 Q3 | 1.16 Million USD | 41.1% |
| 2021 FY | 1.71 Million USD | 184.32% |
| 2021 Q2 | 825.85 Thousand USD | 3.57% |
| 2021 Q4 | 1.71 Million USD | 47.24% |
| 2021 Q1 | 797.41 Thousand USD | 32.14% |
| 2020 Q3 | 617.67 Thousand USD | 78.16% |
| 2020 Q4 | 603.47 Thousand USD | -2.3% |
| 2020 Q1 | 321.03 Thousand USD | 3.23% |
| 2020 FY | 603.47 Thousand USD | 94.04% |
| 2020 Q2 | 346.68 Thousand USD | 7.99% |
| 2019 Q1 | 225.28 Thousand USD | 8.87% |
| 2019 Q4 | 311 Thousand USD | -5.15% |
| 2019 Q2 | 367.16 Thousand USD | 62.98% |
| 2019 Q3 | 327.88 Thousand USD | -10.7% |
| 2019 FY | 311 Thousand USD | 50.29% |
| 2018 Q2 | 156.7 Thousand USD | 55.99% |
| 2018 Q3 | 230.49 Thousand USD | 47.09% |
| 2018 Q4 | 206.93 Thousand USD | -10.22% |
| 2018 FY | 206.93 Thousand USD | 680.14% |
| 2018 Q1 | 100.45 Thousand USD | 278.71% |
| 2017 Q3 | 91.61 Thousand USD | -24.96% |
| 2017 Q4 | 26.52 Thousand USD | -71.05% |
| 2017 FY | 26.52 Thousand USD | -74.71% |
| 2017 Q2 | 122.08 Thousand USD | 46.57% |
| 2017 Q1 | 83.29 Thousand USD | -20.58% |
| 2016 Q4 | 104.87 Thousand USD | -16.58% |
| 2016 Q3 | 125.71 Thousand USD | -29.24% |
| 2016 Q1 | 372.33 Thousand USD | 43.23% |
| 2016 FY | 104.87 Thousand USD | -59.66% |
| 2016 Q2 | 177.66 Thousand USD | -52.28% |
| 2015 FY | 259.96 Thousand USD | 29.2% |
| 2015 Q4 | 259.96 Thousand USD | 360.84% |
| 2015 Q3 | 56.41 Thousand USD | -61.02% |
| 2015 Q2 | 144.7 Thousand USD | -19.92% |
| 2015 Q1 | 180.69 Thousand USD | -10.2% |
| 2014 Q2 | 223.46 Thousand USD | 5.51% |
| 2014 Q1 | 211.79 Thousand USD | 0.45% |
| 2014 FY | 201.21 Thousand USD | -4.57% |
| 2014 Q4 | 201.21 Thousand USD | -30.06% |
| 2014 Q3 | 287.7 Thousand USD | 28.75% |
| 2013 Q2 | 211.29 Thousand USD | -5.6% |
| 2013 Q4 | 210.84 Thousand USD | -3.11% |
| 2013 Q1 | 223.83 Thousand USD | 11.05% |
| 2013 FY | 210.84 Thousand USD | 4.61% |
| 2013 Q3 | 217.61 Thousand USD | 2.99% |
| 2012 Q1 | 3.13 Million USD | -9.46% |
| 2012 Q3 | 234.39 Thousand USD | -92.19% |
| 2012 Q4 | 201.55 Thousand USD | -14.01% |
| 2012 FY | 201.55 Thousand USD | -94.17% |
| 2012 Q2 | 3 Million USD | -4.17% |
| 2011 Q2 | 4.1 Million USD | 25688.2% |
| 2011 FY | 3.45 Million USD | 345861500.0% |
| 2011 Q4 | 3.45 Million USD | -9.43% |
| 2011 Q1 | 15.92 Thousand USD | 1592700.0% |
| 2011 Q3 | 3.81 Million USD | -7.03% |
| 2010 Q3 | 1.00 USD | -100.0% |
| 2010 Q4 | 1.00 USD | 0.0% |
| 2010 Q1 | 71.21 Thousand USD | -77.26% |
| 2010 FY | 1.00 USD | -100.0% |
| 2010 Q2 | 80.63 Thousand USD | 13.22% |
| 2009 Q3 | 649.09 Thousand USD | -37.31% |
| 2009 Q4 | 313.15 Thousand USD | -51.76% |
| 2009 Q2 | 1.03 Million USD | -28.51% |
| 2009 Q1 | 1.44 Million USD | 11151.23% |
| 2009 FY | 313.15 Thousand USD | 2333.0% |
| 2008 Q4 | 12.87 Thousand USD | 139.46% |
| 2008 FY | 12.87 Thousand USD | -76.08% |
| 2008 Q2 | 375.00 USD | -99.17% |
| 2008 Q3 | 5375.00 USD | 1333.33% |
| 2008 Q1 | 45.32 Thousand USD | -15.75% |
| 2007 FY | 53.79 Thousand USD | 0.0% |
| 2007 Q4 | 53.79 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -143320.433% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -69.188% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 68.609% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -500.053% |
| Rebus Holdings, Inc. | 5000.00 USD | -66160.24% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 97.456% |
| Qrons Inc. | 420.00 USD | -788712.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -329.902% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 88.144% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -589.411% |
| Skye Bioscience, Inc. | 11.94 Million USD | 72.254% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 91.472% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 54.112% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4239.016% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.909% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -131.35% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -4478.197% |
| Mesoblast Limited | 667.9 Million USD | 99.504% |
| Marizyme, Inc. | 22.01 Million USD | 84.951% |
| Genus plc | 1.02 Billion USD | 99.678% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -143.899% |
| Pharming Group N.V. | 462.85 Million USD | 99.284% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -563.878% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -428.391% |
| ContraFect Corporation | 20.67 Million USD | 83.979% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -748.694% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -766.879% |
| IMV Inc. | 31.33 Million USD | 89.427% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 20.092% |
| MultiCell Technologies, Inc. | 126.22 USD | -2624691.634% |
| ONE Bio Corp. | 70.08 Million USD | 95.273% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -252.565% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 97.422% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -667.409% |
| Q BioMed Inc. | 3.51 Million USD | 5.76% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 90.582% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1168.008% |
| Biomind Labs Inc. | 73.81 Thousand USD | -4388.021% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.258% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -128.666% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 88.962% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -20.634% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -381.902% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -27.267% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3102.773% |
| Alpha Cognition Inc. | 2.45 Million USD | -35.105% |
| HST Global, Inc. | 1526.00 USD | -217004.325% |
| CSL Limited | 38.02 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -235.336% |
| Halberd Corporation | 10.13 Thousand USD | -32601.727% |
| Enzolytics Inc. | 361.7 Million USD | 99.084% |
| Agentix Corp. | 261.39 Thousand USD | -1167.45% |
| Resverlogix Corp. | 8.11 Million USD | 59.174% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -76.423% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.927% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 93.055% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -417.937% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -14442.873% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 62.98% |
| AVAX Technologies, Inc. | 7.37 Million USD | 55.091% |
| Zenith Capital Corp. | 7410.00 USD | -44610.013% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.902% |
| Ember Therapeutics, Inc. | 184.00 USD | -1800450.0% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -929.506% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1167.585% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -257.021% |
| Kadimastem Ltd | 2.3 Million USD | -43.789% |
| Helix BioMedix, Inc. | 3.02 Million USD | -9.518% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 93.714% |
| BioStem Technologies, Inc. | 14.56 Million USD | 77.246% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -5702.732% |
| LadRx Corporation | 2.3 Million USD | -43.552% |
| Cell Source, Inc. | 195.17 Thousand USD | -1597.492% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -836.893% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -836.893% |
| NovAccess Global Inc. | 62.24 Thousand USD | -5222.279% |
| Affymax, Inc. | 7.44 Million USD | 55.488% |
| Itoco Inc. | 1.4 Million USD | -136.632% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3363.429% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3025.483% |
| Mobile Lads Corp. | 52.00 USD | -6371076.923% |
| CytoDyn Inc. | 11.13 Million USD | 70.25% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2217.245% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -18429.15% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -759.471% |
| SYBLEU INC | 330.46 Thousand USD | -902.521% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -709.192% |
| International Stem Cell Corporation | 5.39 Million USD | 38.534% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2307.047% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 77.916% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 80.017% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -4093.686% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -283.15% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 55.926% |
| Neutra Corp. | 2851.00 USD | -116105.261% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 89.777% |
| PureTech Health plc | 693.97 Million USD | 99.523% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 58.952% |
| IXICO plc | 15.84 Million USD | 79.09% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 59.997% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.794% |
| CSL Limited | 38.02 Billion USD | 99.991% |
| Cellectis S.A. | 333.99 Million USD | 99.008% |